The Duchenne muscular dystrophy (DMD) landscape across the seven major markets (7MM) - the US, France, Germany, Italy, Spain, ...

State of Alaska Department of Revenue reduced its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 1.3% ...

Equities research analysts at Deutsche Bank Aktiengesellschaft assumed coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) in a research report issued on Tuesday, MarketBeat ...

Results show improved functional outcomes for people with Duchenne muscular dystrophy who are ambulatory. Elevidys, which is ...

The company is evaluating whether the drug, which targets cardiac complications, might be used treat patients with other ...

Two healthcare stocks that may or may not be boring, but that regardless look like strong growth stocks to invest in this ...

We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts. In this article, we are going to take a look at where Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands ...

Sarepta Therapeutics (NASDAQ:SRPT) develops RNA-targeted and gene therapies for rare diseases, including treatments for Duchenne muscular dystrophy and ongoing research into new genetic therapies.

LONDON, Jan 31 (Reuters) - Britain's National Health Service (NHS) will provide a cutting-edge gene therapy that aims to cure sickle cell disease, the National Institute for Health and Care ...

Graham said more than 80 patients in the US and EU regions have now been treated with its gene therapy for Duchenne muscular dystrophy, Elevidys (delandistrogene moxeparvovec). Earlier this month, ...

Elevidys, Sarepta's gene therapy for DMD, has emerged as the company's primary growth engine. Following its label expansion to include patients aged 6 years and older, the therapy has seen ...